<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:09:45Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6153554" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6153554</identifier>
        <datestamp>2018-10-09</datestamp>
        <setSpec>springeropen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Invest New Drugs</journal-id>
              <journal-id journal-id-type="iso-abbrev">Invest New Drugs</journal-id>
              <journal-title-group>
                <journal-title>Investigational New Drugs</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0167-6997</issn>
              <issn pub-type="epub">1573-0646</issn>
              <publisher>
                <publisher-name>Springer US</publisher-name>
                <publisher-loc>New York</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6153554</article-id>
              <article-id pub-id-type="pmcid">PMC6153554</article-id>
              <article-id pub-id-type="pmc-uid">6153554</article-id>
              <article-id pub-id-type="pmid">30083962</article-id>
              <article-id pub-id-type="pmid">30083962</article-id>
              <article-id pub-id-type="publisher-id">630</article-id>
              <article-id pub-id-type="doi">10.1007/s10637-018-0630-9</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Phase II Studies</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0508-2987</contrib-id>
                  <name>
                    <surname>Monk</surname>
                    <given-names>Paul</given-names>
                  </name>
                  <address>
                    <phone>614-293-9863</phone>
                    <email>Paul.monk@osumc.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Liu</surname>
                    <given-names>Glenn</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stadler</surname>
                    <given-names>Walter M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Geyer</surname>
                    <given-names>Susan</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Huang</surname>
                    <given-names>Ying</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wright</surname>
                    <given-names>John</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Villalona-Calero</surname>
                    <given-names>Miguel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wade</surname>
                    <given-names>James</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Szmulewitz</surname>
                    <given-names>Russell</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gupta</surname>
                    <given-names>Shilpa</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mortazavi</surname>
                    <given-names>Amir</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dreicer</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pili</surname>
                    <given-names>Roberto</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dawson</surname>
                    <given-names>Nancy</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff13">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>George</surname>
                    <given-names>Saby</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff14">14</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Garcia</surname>
                    <given-names>Jorge A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff15">15</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2285 7943</institution-id><institution-id institution-id-type="GRID">grid.261331.4</institution-id><institution>Ohio State University, </institution></institution-wrap>A433b Starling-Loving Hall, 310 W. 10th ave, Columbus, OH 43082 USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9209 0955</institution-id><institution-id institution-id-type="GRID">grid.412647.2</institution-id><institution>University of Wisconsin Carbone Cancer Center, </institution></institution-wrap>1111 Highland Ave, Madison, WI 53705 USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7822</institution-id><institution-id institution-id-type="GRID">grid.170205.1</institution-id><institution>University of Chicago, </institution></institution-wrap>5841 S Maryland Ave, Chicago, IL 60637 USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2353 285X</institution-id><institution-id institution-id-type="GRID">grid.170693.a</institution-id><institution>University of South Florida, </institution></institution-wrap>4202 E Fowler Ave, Tampa, FL 33620 USA </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2285 7943</institution-id><institution-id institution-id-type="GRID">grid.261331.4</institution-id><institution>Ohio State University, </institution></institution-wrap>320 W 10th Ave, Columbus, OH 43210-1280 USA </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8075</institution-id><institution-id institution-id-type="GRID">grid.48336.3a</institution-id><institution>National Cancer Institute, </institution></institution-wrap>9609 Medical Center Dr., MSC, Bethesda, MD 9739 USA </aff>
                <aff id="Aff7"><label>7</label>Miami Cancer Institute, 8900 N Kendall Dr, Miami, FL 33176-2118 USA </aff>
                <aff id="Aff8"><label>8</label>Cancer Care Specialists of Central Illinois, 210 W Mckinley Ave, Decatur, IL 62526 USA </aff>
                <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 8736 9513</institution-id><institution-id institution-id-type="GRID">grid.412578.d</institution-id><institution>University of Chicago Medical Center, </institution></institution-wrap>5841 S Maryland Ave # MC2115, Chicago, IL 60637-1447 USA </aff>
                <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000000419368657</institution-id><institution-id institution-id-type="GRID">grid.17635.36</institution-id><institution>University of Minnesota, </institution></institution-wrap>420 Delaware St SE, Minneapolis, MN 55455-0341 USA </aff>
                <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9136 933X</institution-id><institution-id institution-id-type="GRID">grid.27755.32</institution-id><institution>University of Virginia School of Medicine, </institution></institution-wrap>PO Box 800716, Charlottesville, VA 22908-0716 USA </aff>
                <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2287 3919</institution-id><institution-id institution-id-type="GRID">grid.257413.6</institution-id><institution>Indiana University, </institution></institution-wrap>535 Barnhill Drive, Indianapolis, IN 46202 USA </aff>
                <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1955 1644</institution-id><institution-id institution-id-type="GRID">grid.213910.8</institution-id><institution>Georgetown-Lombardi Comprehensive Cancer Center, </institution></institution-wrap>3800 Reservoir Rd NW, Washington, DC 20007-2113 USA </aff>
                <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2181 8635</institution-id><institution-id institution-id-type="GRID">grid.240614.5</institution-id><institution>Roswell Park Cancer Institute, </institution></institution-wrap>6 Symphony Cir, Orchard Park, NY 14127 USA </aff>
                <aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0675 4725</institution-id><institution-id institution-id-type="GRID">grid.239578.2</institution-id><institution>Taussig Cancer Institute, </institution></institution-wrap>9500 Euclid Ave, Cleveland, OH 44195-0001 USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>7</day>
                <month>8</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>7</day>
                <month>8</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2018</year>
              </pub-date>
              <volume>36</volume>
              <issue>5</issue>
              <fpage>919</fpage>
              <lpage>926</lpage>
              <history>
                <date date-type="received">
                  <day>20</day>
                  <month>4</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>25</day>
                  <month>6</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2018</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <title>Summary</title>
                <p id="Par1"><italic>Background</italic> Tivantinib is a non-ATP competitive inhibitor of c-MET receptor tyrosine kinase that may have additional cytotoxic mechanisms including tubulin inhibition. Prostate cancer demonstrates higher c-MET expression as the disease progresses to more advanced stages and to a castration resistant state. <italic>Methods</italic> 80 patients (pts) with asymptomatic or minimally symptomatic mCRPC were assigned (2:1) to either tivantinib 360 mg PO BID or placebo (P). The primary endpoint was progression free survival (PFS). <italic>Results</italic> Of the 80 pts. enrolled, 78 (52 tivantinib, 26 P) received treatment and were evaluable. Median follow up is 8.9 months (range: 2.3 to 19.6 months). Patients treated with tivantinib had significantly better PFS vs. those treated with placebo (medians: 5.5 mo vs 3.7 mo, respectively; HR = 0.55, 95% CI: 0.33 to 0.90; <italic>p</italic> = 0.02). Grade 3 febrile neutropenia was seen in 1 patient on tivantinib while grade 3 and 4 neutropenia was recorded in 1 patient each on tivantinib and placebo. Grade 3 sinus bradycardia was recorded in two men on the tivantinib arm. <italic>Conclusions</italic> Tivantinib has mild toxicity and improved PFS in men with asymptomatic or minimally symptomatic mCRPC.</p>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Tivantinib</kwd>
                <kwd>Castration resistant</kwd>
                <kwd>Prostate</kwd>
                <kwd>Cancer</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id>
                      <institution>National Cancer Institute</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>HHSN261201100070C</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Monk</surname>
                      <given-names>Paul</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© Springer Science+Business Media, LLC, part of Springer Nature 2018</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Introduction</title>
              <p id="Par2">Metastatic castration resistant prostate cancer (mCRPC) is the lethal version of this common disease. Prostate cancer reaches this point through the combined events of metastasis and adaptation by the tumor to a low testosterone environment. The overall survival of men with mCRPC has improved over the past few years with the introduction of several different agents with non-overlapping mechanisms of action. [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR5">5</xref>] Despite this progress, further improvement is needed as men with mCRPC still invariably succumb to this disease.</p>
            </sec>
            <sec id="Sec2">
              <title>C-MET and prostate cancer</title>
              <p id="Par3">Hepatocyte growth factor (HGF) and its receptor N-methyl-N′-nitrosoguanidine human osteosarcoma transforming gene (MET) seem to play important roles in the metastatic process [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>] and its signaling is abnormal in a variety of malignancies [<xref ref-type="bibr" rid="CR8">8</xref>]. Serum HGF levels are higher in metastatic prostate cancer than in localized tumors [<xref ref-type="bibr" rid="CR9">9</xref>] and has been associated with poorer outcomes. [<xref ref-type="bibr" rid="CR10">10</xref>] Xenograft and in vitro data reveal that MET expression increases following androgen deprivation suggesting an association with the development of castrate resistant disease. [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]</p>
            </sec>
            <sec id="Sec3">
              <title>Tivantinib</title>
              <p id="Par4">Tivantinib (ARQ 197; ArQule, Burlington, MA; Daichi-Sankyo, Tokyo, Japan) is an orally available selective small molecule that inhibits MET receptor tyrosine kinase with a novel ATP independent binding (allosteric inhibitor) mechanism, leading to inhibition of cell proliferation and induction of apoptosis in MET-expressing cancer cells. [<xref ref-type="bibr" rid="CR13">13</xref>] [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>] Tivantinib has been found to have additional properties and in some preclinical studies its anti-cancer properties were independent of the c-MET inhibition. [<xref ref-type="bibr" rid="CR16">16</xref>] Together, these findings supported the hypothesis that tivantinib would have activity against mCRPC. We therefore performed a phase II randomized placebo controlled trial of tivantinib in men with asymptomatic or minimally symptomatic mCRPC.</p>
            </sec>
            <sec id="Sec4">
              <title>Patients and methods</title>
              <sec id="Sec5">
                <title>Eligibility criteria</title>
                <p id="Par5">Eligible men were required to have metastatic histologically confirmed prostate adenocarcinoma, castrate testosterone level (&lt;50 ng/dL), to be asymptomatic or minimally symptomatic (no symptoms attributable to prostate cancer greater than Grade 1), ECOG ≤2, and PSA ≥ 2 ng/ml. Prior treatment with sipuleucel- T and abiraterone acetate were allowed. Prior chemotherapy was not allowed unless used in a perioperative setting and completed &gt;6 months prior to enrollment. Progressive disease at study entry was required and defined as two successive rises in PSA separated at least by one week, appearance of two or more new lesions on bone scan, &gt; 20% objective increase in size of target lesion. This is consistent with Prostate Cancer Working Group 2 guidelines (PCWG2) for trials in advanced prostate cancer. [<xref ref-type="bibr" rid="CR17">17</xref>] Bone targeting agents such as zoledronic acid or denosumab were permitted provided patients began therapy prior to study entry. Normal organ and bone marrow function were required. Exclusion criteria included radiotherapy within 4 weeks, uncontrolled intercurrent illness, known brain metastasis, history of myocardial infarction or unstable angina within 6 months, history of severely impaired lung function, active liver disease, poorly controlled diabetes, or impairment of gastrointestinal function. Institutional review board approval was obtained for all study procedures at each participating site. Each patient provided written informed consent.</p>
              </sec>
              <sec id="Sec6">
                <title>Treatment plan</title>
                <p id="Par6">Participants were stratified based on prior treatment with abiraterone acetate and sipuleucel-T and randomly allocated at a ratio of 2:1 to receive tivantinib or placebo in a double-blind fashion. Patients received twice-daily dosing of 360 mg tivantinib by mouth or matched placebo. One cycle was 28 days. At the time of disease progression, the blind could be broken and those assigned to the placebo arm were allowed to cross over to tivantinib. At the time of the trial conduct, abiraterone acetate was approved only in the post-docetaxel setting, and neither enzalutamide nor radium223 were approved. Therefore, placebo in this clinical setting was felt to be appropriate.</p>
              </sec>
              <sec id="Sec7">
                <title>Efficacy outcome measures</title>
                <p id="Par7">We used PCWG2 guidelines to define disease progression which included need for palliative radiation or surgery, RECIST 1.1 defined progression, the appearance of ≥2 new bone lesions on Tc<sup>99</sup>MDP bone scan (with instructions for recognizing flare). Investigator determined clinical deterioration was also considered progression. Rising PSA levels alone while on study drug were not considered disease progression. Toxicity was evaluated using National Cancer Institute Common Toxicity Criteria (version 4.0).</p>
              </sec>
              <sec id="Sec8">
                <title>Pretreatment and follow-up evaluations</title>
                <p id="Par8">At baseline, participants underwent complete history, physical examination and laboratory testing. Baseline imaging was completed ≤4 weeks prior to start of treatment. Patients were evaluated every 4 weeks with repeat examination, safety assessment and standard laboratory testing. Whole body bone imaging, CT of abdomen/pelvis and chest X-ray were performed every 12 weeks or as needed for symptoms suggestive of disease progression.</p>
              </sec>
              <sec id="Sec9">
                <title>Statistical considerations</title>
                <p id="Par9">The primary endpoint in this trial was to compare the PFS of tivantinib vs placebo. This was defined as the time from study entry (start of blinded treatment) to the date of documented progression and/or death, censoring alive and progression-free patients at their last follow-up date. In this trial, the proposed sample size of 78 eligible and evaluable patients (26 in the placebo arm, 52 in the tivantinib arm) provided 90% power to detect an improvement from 3 months median PFS with placebo to a median PFS of at least 6 months with the tivantinib treatment, and a Type I error rate of 0.10 was assumed for this one-sided test. This sample size was based on a log-rank test calculation using the R statistical program (gsDesign package, R version 2.11.1).</p>
                <p id="Par10">Since this was a phase II trial with a direct comparison between the treatment arm and a placebo-control arm, we relaxed the Type I error constraint to 0.10. [<xref ref-type="bibr" rid="CR18">18</xref>] Progression free survival curves based on observed data were constructed using the Kaplan-Meier method, and Cox proportional hazards model was used to estimate the hazard ratio of treatment vs. placebo. Adverse events as defined by NCI CTCAE v4.0 were summarized using descriptive statistics, where the maximum grade for each type of toxicity was recorded for each patient, and frequency tables were made to determine toxicity patterns.</p>
              </sec>
            </sec>
            <sec id="Sec10">
              <title>Results</title>
              <sec id="Sec11">
                <title>Patient characteristics</title>
                <p id="Par11">Between January 2012 and September 2013 eighty men with asymptomatic or minimally symptomatic CRPC were enrolled in this multicenter, double-blind phase II trial. Seventy eight men (52 randomly assigned to tivantinib and 26 to matching placebo) started treatment and were included in safety and efficacy analysis. <bold>(</bold>Fig. <xref rid="Fig1" ref-type="fig">1</xref><bold>)</bold> Groups were well balanced for most baseline characteristics <bold>(</bold>Table <xref rid="Tab1" ref-type="table">1</xref><bold>)</bold>. A higher proportion of men self-identifying as African American and men with lymph node involvement were randomized to placebo. There was no prior treatment with Radium-223, enzalutamide or chemotherapy while nearly a third of patients received prior abiraterone acetate and/or sipuleucel-T.<fig id="Fig1"><label>Fig. 1</label><caption><p>CONSORT diagram</p></caption><graphic xlink:href="10637_2018_630_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline Characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Overall<break/><italic>N</italic> = 78</th><th>Tivantinib<break/><italic>N</italic> = 52</th><th>Placebo<break/><italic>N</italic> = 26</th><th>P-value</th></tr></thead><tbody><tr><td>Age at study entry<break/>Median (range)</td><td>67 (43–85)</td><td>67 (43–84)</td><td>66.5 (48–85)</td><td>0.93</td></tr><tr><td colspan="5">Race</td></tr><tr><td> Asian</td><td>1 (1%)</td><td>1 (2%)</td><td>0</td><td rowspan="3">0.015</td></tr><tr><td> African American</td><td>8 (10%)</td><td>2 (4%)</td><td>6 (23%)</td></tr><tr><td> Caucasian</td><td>69 (88%</td><td>49 (94%)</td><td>20 (77%)</td></tr><tr><td colspan="5">Ethnicity</td></tr><tr><td> non-Hispanic</td><td>75 (96%)</td><td>49 (94%)</td><td>26</td><td rowspan="2">0.55</td></tr><tr><td> unknown</td><td>3 (4%)</td><td>3 (6%)</td><td>0</td></tr><tr><td colspan="5">ECOG PS</td></tr><tr><td> 0</td><td>65 (83%)</td><td>42 (81%)</td><td>23 (88%)</td><td rowspan="2">0.53</td></tr><tr><td> 1</td><td>13 (17%)</td><td>10 (19%)</td><td>3 (12%)</td></tr><tr><td colspan="5">Gleason Score</td></tr><tr><td>  &lt; 7</td><td>9 (13%)</td><td>5(12%)</td><td>4 (16%)</td><td rowspan="4">0.25</td></tr><tr><td> 7</td><td>17 25%)</td><td>10 (23%)</td><td>7 (29%)</td></tr><tr><td>  &gt; 7</td><td>41 (61%)</td><td>28(65%)</td><td>13(54%)</td></tr><tr><td> missing</td><td>11</td><td>9</td><td>2</td></tr><tr><td colspan="5">PSA</td></tr><tr><td> median (range)</td><td>16.75 (2.2 to 868)</td><td>13.6 (2.3 to 868)</td><td>26.7 (2.2 to 579)</td><td>0.28</td></tr><tr><td colspan="5">Alk phos</td></tr><tr><td> median (range)</td><td>80 (16 to 423)</td><td>80.5 (41 to 423)</td><td>78 (16 to 322)</td><td rowspan="2">0.90</td></tr><tr><td> missing</td><td>1</td><td>0</td><td>1</td></tr><tr><td colspan="5">LDH</td></tr><tr><td> median (range)</td><td>192 (111 to 770)</td><td>186 (126 to 770)</td><td>196 (111 to 467)</td><td rowspan="2">0.89</td></tr><tr><td> missing</td><td>5</td><td>4</td><td>1</td></tr><tr><td colspan="5">Hemoglobin</td></tr><tr><td> median (range)</td><td>13 (10.1 to 38.9)</td><td>13.1 (10.6 to 38.9)</td><td>12.9 (10.1 to 14.5)</td><td>0.53</td></tr><tr><td colspan="5">Bone involvement</td></tr><tr><td> yes</td><td>50 (64%)</td><td>32 (62%)</td><td>18 (69%)</td><td rowspan="2">0.50</td></tr><tr><td> no</td><td>28 (36%)</td><td>20 (38%)</td><td>8 (31%)</td></tr><tr><td colspan="5">Lymph node involvement</td></tr><tr><td> yes</td><td>17 (22%)</td><td>8 (15%)</td><td>9 (35%)</td><td rowspan="2">0.052</td></tr><tr><td> no</td><td>61 (78%)</td><td>44 (85%)</td><td>17 (65%)</td></tr><tr><td colspan="5">Lung involvement</td></tr><tr><td> yes</td><td>5 (6%)</td><td>2 (4%)</td><td>3 (12%)</td><td rowspan="2">0.33</td></tr><tr><td> no</td><td>73 (94%)</td><td>50 (96%)</td><td>23 (88%)</td></tr><tr><td colspan="5">Other organ involvement*</td></tr><tr><td> yes</td><td>12 (15%)</td><td>9 (17%)</td><td>3 (12%)</td><td rowspan="2">0.74</td></tr><tr><td> no</td><td>66 (85%)</td><td>43 (83%)</td><td>23 (88%)</td></tr><tr><td colspan="5">Prior Treatment</td></tr><tr><td colspan="5"> Sipuleucel-T</td></tr><tr><td>  yes</td><td>24 (31%)</td><td>16 (31%)</td><td>8 (31%)</td><td rowspan="2">0.999</td></tr><tr><td>  no</td><td>54 (69%)</td><td>36 (69%)</td><td>18 (69%)</td></tr><tr><td colspan="5"> Abiraterone</td></tr><tr><td>  yes</td><td>23 (29%)</td><td>16 (31%)</td><td>7 (27%)</td><td rowspan="2">0.73</td></tr><tr><td>  no</td><td>55 (71%)</td><td>36 (69%)</td><td>19 (73%)</td></tr></tbody></table></table-wrap></p>
              </sec>
              <sec id="Sec12">
                <title>Efficacy</title>
                <p id="Par12">At the time of primary PFS analysis, 68 patients had progressed and/or died (26/26 on placebo and 42/52 on tivantinib). The median follow-up on event-free patients was 8.9 months (range: 2.3 to 19.6 months). The median PFS for those on the placebo arm was 3.7 months (95% CI: 2.7 to 5.4 months) vs. a median PFS of 5.5 months for those treated with tivantinib (95% CI: 3.2 to 8.0 months). <bold>(</bold>Fig. <xref rid="Fig2" ref-type="fig">2</xref><bold>).</bold><fig id="Fig2"><label>Fig. 2</label><caption><p>Progression Free Survival Curves</p></caption><graphic xlink:href="10637_2018_630_Fig2_HTML" id="MO2"/></fig></p>
                <p id="Par13">A partial response by RECIST was documented in 1 patient randomized to tivantinib. <bold>(</bold>Fig. <xref rid="Fig3" ref-type="fig">3</xref><bold>)</bold> Genomic profiling of this individual with an exceptional response revealed high androgen receptor amplification but no other significant alterations.PSA increases were generally seen on both arms. <bold>(</bold>Fig. <xref rid="Fig4" ref-type="fig">4</xref><bold>).</bold><fig id="Fig3"><label>Fig. 3</label><caption><p>Pulmonary metastasis response to tivantinib</p></caption><graphic xlink:href="10637_2018_630_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Maximum Decline/Minimum increase in PSA during study</p></caption><graphic xlink:href="10637_2018_630_Fig4_HTML" id="MO4"/></fig></p>
                <p id="Par14">Crossover from placebo to tivantinib was allowed at the time of progression. 12 of the 26 patients assigned to placebo when they progressed received tivantinib. The median time on tivantinib for this group was 4.3 months with a range of 2 to 10 months. One of the 12 experienced an objective partial response by RECIST. Overall survival was not measured.</p>
              </sec>
              <sec id="Sec13">
                <title>Safety</title>
                <p id="Par15">Toxicity is summarized in Table <xref rid="Tab2" ref-type="table">2</xref><bold>.</bold> Grade (G) 3 febrile neutropenia was seen in 1 patient on tivantinib while G3 and 4 neutropenia was recorded in 1 patient each on tivantinib and placebo. G3 sinus bradycardia was recorded in two men on the tivantinib arm. Eleven deaths (4 placebo and 7 tivantinib) were recorded during the trial and were all determined to be unrelated to therapy.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Grade 3+ Adverse Events regardless of attribution</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>*T (n = 52)<break/>*P (n = 26)</th><th>Grade 3/4</th><th>Grade 5</th></tr></thead><tbody><tr><td rowspan="2">Acute coronary syndrome</td><td>T</td><td>1(2)</td><td>0(0)</td></tr><tr><td>P</td><td>0(0)</td><td>0(0)</td></tr><tr><td rowspan="2">Back Pain</td><td>T</td><td>1(2)</td><td>0(0)</td></tr><tr><td>P</td><td>2(8)</td><td>0(0)</td></tr><tr><td rowspan="2">Confusion</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>2(8)</td><td>0(0)</td></tr><tr><td rowspan="2">Death NOS</td><td>T</td><td>1(2)</td><td>1(2)</td></tr><tr><td>P</td><td>0(0)</td><td>1(4)</td></tr><tr><td rowspan="2">Dehydration</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>3(12)</td><td>0(0)</td></tr><tr><td rowspan="2">Duodenal ulcer</td><td>T</td><td>1(2)</td><td>0(0)</td></tr><tr><td>P</td><td>0(0)</td><td>0(0)</td></tr><tr><td rowspan="2">Dyspnea</td><td>T</td><td>1(2)</td><td>0(0)</td></tr><tr><td>P</td><td>0(0)</td><td>0(0)</td></tr><tr><td rowspan="2">Dizziness</td><td>T</td><td>1(2)</td><td>0(0)</td></tr><tr><td>P</td><td>0(0)</td><td>0(0)</td></tr><tr><td rowspan="2">Fall</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>1(4)</td><td>0(0)</td></tr><tr><td rowspan="2">Fatigue</td><td>T</td><td>2(4)</td><td>0(0)</td></tr><tr><td>P</td><td>0(0)</td><td>0(0)</td></tr><tr><td rowspan="2">Gait disturbance</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>1(4)</td><td>0(0)</td></tr><tr><td rowspan="2">Generalized muscle weakness</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>1(4)</td><td>0(0)</td></tr><tr><td rowspan="2">Hypertension</td><td>T</td><td>1(2)</td><td>0(0)</td></tr><tr><td>P</td><td>0(0)</td><td>0(0)</td></tr><tr><td rowspan="2">Hypokalemia</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>1(4)</td><td>0(0)</td></tr><tr><td rowspan="2">Hyponatremia</td><td>T</td><td>1(2)</td><td>0(0)</td></tr><tr><td>P</td><td>0(0)</td><td>0(0)</td></tr><tr><td rowspan="2">Hypotension</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>1(4)</td><td>0(0)</td></tr><tr><td rowspan="2">Hypoxia</td><td>T</td><td>1(2)</td><td>1(2)</td></tr><tr><td>P</td><td>0(0)</td><td>0(0)</td></tr><tr><td rowspan="2">Infections</td><td>T</td><td>1(2)</td><td>0(0)</td></tr><tr><td>P</td><td>3(12)</td><td>0(0)</td></tr><tr><td rowspan="2">Musculoskeletal and connective tissue disorder - Other</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>1(4)</td><td>0(0)</td></tr><tr><td rowspan="2">Neoplasms benign, malignant and unspecified</td><td>T</td><td>0(0)</td><td>1(2)</td></tr><tr><td>P</td><td>1(4)</td><td>0(0)</td></tr><tr><td rowspan="2">Nervous system disorders – Other</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>1(4)</td><td>0(0)</td></tr><tr><td rowspan="2">Pleural effusion</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>1(4)</td><td>0(0)</td></tr><tr><td rowspan="2">Sinus bradycardia</td><td>T</td><td>3(6)</td><td>0(0)</td></tr><tr><td>P</td><td>0(0)</td><td>0(0)</td></tr><tr><td rowspan="2">Sinus Tachycardia</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>1(4)</td><td>0(0)</td></tr><tr><td rowspan="2">Syncope</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>2(8)</td><td>0(0)</td></tr><tr><td rowspan="2">Thromboembolic event</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>1(4)</td><td>0(0)</td></tr><tr><td rowspan="2">Tumor Pain</td><td>T</td><td>1(2)</td><td>0(0)</td></tr><tr><td>P</td><td>0(0)</td><td>0(0)</td></tr><tr><td rowspan="2">Urinary tract obstruction</td><td>T</td><td>0(0)</td><td>0(0)</td></tr><tr><td>P</td><td>1(4)</td><td>0(0)</td></tr><tr><td>Hematologic AE, no (%)</td><td>Arm</td><td>Grade 3</td><td>Grade 4</td></tr><tr><td rowspan="2">Anemia</td><td>*T</td><td>3(6)</td><td>0(0)</td></tr><tr><td>*P</td><td>2(8)</td><td>0(0)</td></tr><tr><td rowspan="2">Febrile neutropenia</td><td>T</td><td>1(2)</td><td>0(0)</td></tr><tr><td>P</td><td>0(0)</td><td>0(0)</td></tr><tr><td rowspan="2">Neutrophil count decreased</td><td>T</td><td>1(2)</td><td>1(2)</td></tr><tr><td>P</td><td>1(4)</td><td>1(4)</td></tr><tr><td rowspan="2">Platelet count decreased</td><td>T</td><td>1(2)</td><td>0(0)</td></tr><tr><td>P</td><td>0(0)</td><td>0(0)</td></tr><tr><td rowspan="2">White blood cell decreased</td><td>T</td><td>1(2)</td><td>1(2)</td></tr><tr><td>P</td><td>2(8)</td><td>0(0)</td></tr></tbody></table><table-wrap-foot><p>*T = tivantinib, P = placebo</p></table-wrap-foot></table-wrap></p>
              </sec>
            </sec>
            <sec id="Sec14">
              <title>Discussion</title>
              <p id="Par16">Treatment with tivantinib was associated with minimal toxicity and a significantly longer PFS when compared to placebo in men with asymptomatic or minimally symptomatic mCRPC. In comparing the PFS distributions between treatment arms, the <italic>p</italic>-value for the log-rank test was <italic>p</italic> = 0.02. Furthermore, this p-value reflects a two-sided alternative hypothesis, which is more stringent than what was designed in this trial. Tivantinib’s favorable side effect profile has been demonstrated in various clinical trial settings, but these studies failed to achieve their respective primary endpoints. [<xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR23">23</xref>] This broad lack of efficacy is seen despite an underlying biologic rationale that is similar to the current trial. Several factors should be considered when interpreting the results of the present trial. First, the strengths of our report include the randomized design, the use of PCWG2 guidelines to determine progression and the control arm performed as expected. However, this study’s small size makes it more sensitive to biases that are potentially unaccounted for. More troublesome is the uncertainty of both the underlying mechanism of action of tivantinib and the value of PFS as an important endpoint in mCRPC trials. During the conduct of this trial, preclinical studies reported tivantinib’s activity is not via the inhibition of c-MET/HGF signaling. [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR24">24</xref>] [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] Rather, the in vitro activity is more consistent with a cytotoxic agent. Targeting MET therefore remains unproven as a strategy that produces clinical benefit in men with mCRPC. [<xref ref-type="bibr" rid="CR27">27</xref>]</p>
              <p id="Par17">The inability to rely on intermediate endpoints to predict overall survival in mCRPC is problematic. [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR28">28</xref>–<xref ref-type="bibr" rid="CR30">30</xref>] This must be considered when we interpret the significant improvement in PFS seen in this study. The experience with cabozantinib’s development in mCRPC is perhaps most instructive. [<xref ref-type="bibr" rid="CR31">31</xref>] Cabozantinib, a potent inhibitor of MET and VEGFR2, failed to improve overall survival (OS) when compared with prednisone in heavily treated men with mCRPC. These negative phase III results were accompanied by significant improvements in bone scan response, radiographic PFS, circulating tumor cell conversions, time to first symptomatic skeletal event and favorable bone biomarker changes. One potential explanation for the lack of OS benefit is the high number of dose reductions and discontinuations for toxicity. The phase II experience was associated with unprecedented tumor regression in the majority with soft tissue disease, normalization of bone scans in 12% and improvement in bone pain in 67%. [<xref ref-type="bibr" rid="CR32">32</xref>] This apparent paradox seems most acute in advanced prostate cancer trials but it has been seen in other tumor types and caution has been advised when making conclusions with PFS data. [<xref ref-type="bibr" rid="CR33">33</xref>]</p>
            </sec>
            <sec id="Sec15">
              <title>Conclusion</title>
              <p id="Par18">Tivantinib has mild toxicity and significantly improved PFS compared to placebo in men with asymptomatic/minimally symptomatic mCRPC. The magnitude of benefit does not support further evaluation as a single agent. Optimal further development of tivantinib in mCRPC would ideally include a better understanding of the drug’s underlying mechanism of action. This would better inform combination studies with other therapies in mCRPC.</p>
            </sec>
          </body>
          <back>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>This project has been funded by the National Cancer Institute under Contract No. HHSN261201100070C.</p>
            </notes>
            <notes notes-type="COI-statement">
              <sec id="FPar1">
                <title>Conflicts of interests</title>
                <p>The authors have no relevant conflicts of interests to report.</p>
              </sec>
              <sec id="FPar2">
                <title>Ethical approval</title>
                <p>All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This trial was approved by each participating institution’s Institutional Review Board.</p>
              </sec>
              <sec id="FPar3">
                <title>Informed consent</title>
                <p>Informed consent was obtained from all individual participants included in the study.</p>
              </sec>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fizazi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Scher</surname>
                      <given-names>HI</given-names>
                    </name>
                    <name>
                      <surname>Molina</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Logothetis</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Chi</surname>
                      <given-names>KN</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Staffurth</surname>
                      <given-names>JN</given-names>
                    </name>
                    <name>
                      <surname>North</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Vogelzang</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>Saad</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Mainwaring</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Harland</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Goodman OB Jr</surname>
                    </name>
                    <name>
                      <surname>Sternberg</surname>
                      <given-names>CN</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Kheoh</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Haqq</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>de Bono</surname>
                      <given-names>JS</given-names>
                    </name>
                    <collab>COU-AA-301 Investigators</collab>
                  </person-group>
                  <article-title>Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study</article-title>
                  <source>Lancet Oncol</source>
                  <year>2012</year>
                  <volume>13</volume>
                  <issue>10</issue>
                  <fpage>983</fpage>
                  <lpage>992</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1470-2045(12)70379-0</pub-id>
                  <?supplied-pmid 22995653?>
                  <pub-id pub-id-type="pmid">22995653</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kantoff</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Higano</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Shore</surname>
                      <given-names>ND</given-names>
                    </name>
                    <name>
                      <surname>Berger</surname>
                      <given-names>ER</given-names>
                    </name>
                    <name>
                      <surname>Small</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Penson</surname>
                      <given-names>DF</given-names>
                    </name>
                    <name>
                      <surname>Redfern</surname>
                      <given-names>CH</given-names>
                    </name>
                    <name>
                      <surname>Ferrari</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Dreicer</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Sims</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Frohlich</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Schellhammer</surname>
                      <given-names>PF</given-names>
                    </name>
                    <collab>IMPACT Study Investigators</collab>
                  </person-group>
                  <article-title>Sipuleucel-T immunotherapy for castration-resistant prostate cancer</article-title>
                  <source>N Engl J Med</source>
                  <year>2010</year>
                  <volume>363</volume>
                  <issue>5</issue>
                  <fpage>411</fpage>
                  <lpage>422</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1001294</pub-id>
                  <?supplied-pmid 20818862?>
                  <pub-id pub-id-type="pmid">20818862</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scher</surname>
                      <given-names>HI</given-names>
                    </name>
                    <name>
                      <surname>Fizazi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Saad</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Taplin</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Sternberg</surname>
                      <given-names>CN</given-names>
                    </name>
                    <name>
                      <surname>Miller</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>de Wit</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Mulders</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Chi</surname>
                      <given-names>KN</given-names>
                    </name>
                    <name>
                      <surname>Shore</surname>
                      <given-names>ND</given-names>
                    </name>
                    <name>
                      <surname>Armstrong</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Flaig</surname>
                      <given-names>TW</given-names>
                    </name>
                    <name>
                      <surname>Fléchon</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Mainwaring</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Fleming</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Hainsworth</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Hirmand</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Selby</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Seely</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>de Bono</surname>
                      <given-names>JS</given-names>
                    </name>
                    <collab>AFFIRM Investigators</collab>
                  </person-group>
                  <article-title>Increased survival with Enzalutamide in prostate Cancer after chemotherapy</article-title>
                  <source>N Engl J Med</source>
                  <year>2012</year>
                  <volume>367</volume>
                  <fpage>1187</fpage>
                  <lpage>1197</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1207506</pub-id>
                  <?supplied-pmid 22894553?>
                  <pub-id pub-id-type="pmid">22894553</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <mixed-citation publication-type="other">de Bono, J.S., et al., <italic>Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.</italic> Lancet. <bold>376</bold>(9747): p. 1147–54</mixed-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Parker</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Nilsson</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Heinrich</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Helle</surname>
                      <given-names>SI</given-names>
                    </name>
                    <name>
                      <surname>O'Sullivan</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Fosså</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Chodacki</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Wiechno</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Logue</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Seke</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Widmark</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Johannessen</surname>
                      <given-names>DC</given-names>
                    </name>
                    <name>
                      <surname>Hoskin</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Bottomley</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>James</surname>
                      <given-names>ND</given-names>
                    </name>
                    <name>
                      <surname>Solberg</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Syndikus</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Kliment</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Wedel</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Boehmer</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Dall'Oglio</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Franzén</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Coleman</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Vogelzang</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>O'Bryan-Tear</surname>
                      <given-names>CG</given-names>
                    </name>
                    <name>
                      <surname>Staudacher</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Garcia-Vargas</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Shan</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bruland</surname>
                      <given-names>ØS</given-names>
                    </name>
                    <name>
                      <surname>Sartor</surname>
                      <given-names>O</given-names>
                    </name>
                    <collab>ALSYMPCA Investigators</collab>
                  </person-group>
                  <article-title>Alpha emitter radium-223 and survival in metastatic prostate cancer</article-title>
                  <source>N Engl J Med</source>
                  <year>2013</year>
                  <volume>369</volume>
                  <issue>3</issue>
                  <fpage>213</fpage>
                  <lpage>223</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1213755</pub-id>
                  <?supplied-pmid 23863050?>
                  <pub-id pub-id-type="pmid">23863050</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lesko</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Majka</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>The biological role of HGF-MET axis in tumor growth and development of metastasis</article-title>
                  <source>Front Biosci</source>
                  <year>2008</year>
                  <volume>13</volume>
                  <fpage>1271</fpage>
                  <lpage>1280</lpage>
                  <pub-id pub-id-type="doi">10.2741/2760</pub-id>
                  <?supplied-pmid 17981628?>
                  <pub-id pub-id-type="pmid">17981628</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Matsumoto</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Nakamura</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>Hepatocyte growth factor and the met system as a mediator of tumor-stromal interactions</article-title>
                  <source>Int J Cancer</source>
                  <year>2006</year>
                  <volume>119</volume>
                  <issue>3</issue>
                  <fpage>477</fpage>
                  <lpage>483</lpage>
                  <pub-id pub-id-type="doi">10.1002/ijc.21808</pub-id>
                  <?supplied-pmid 16453287?>
                  <pub-id pub-id-type="pmid">16453287</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <mixed-citation publication-type="other">Liu, X., R.C. Newton, and P.A. Scherle, <italic>Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.</italic> Trends Mol Med. <bold>16</bold>(1): p. 37–45</mixed-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Naughton</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer</article-title>
                  <source>J Urol</source>
                  <year>2001</year>
                  <volume>165</volume>
                  <issue>4</issue>
                  <fpage>1325</fpage>
                  <lpage>1328</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0022-5347(01)69893-8</pub-id>
                  <?supplied-pmid 11257710?>
                  <pub-id pub-id-type="pmid">11257710</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Humphrey</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Halabi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Picus</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sanford</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Vogelzang</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>Small</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Kantoff</surname>
                      <given-names>PW</given-names>
                    </name>
                  </person-group>
                  <article-title>Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480</article-title>
                  <source>Clin Genitourin Cancer</source>
                  <year>2006</year>
                  <volume>4</volume>
                  <issue>4</issue>
                  <fpage>269</fpage>
                  <lpage>274</lpage>
                  <pub-id pub-id-type="doi">10.3816/CGC.2006.n.006</pub-id>
                  <?supplied-pmid 16729910?>
                  <pub-id pub-id-type="pmid">16729910</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Verras</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Xue</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>TH</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Sun</surname>
                      <given-names>Z</given-names>
                    </name>
                  </person-group>
                  <article-title>The androgen receptor negatively regulates the expression of c-met: implications for a novel mechanism of prostate cancer progression</article-title>
                  <source>Cancer Res</source>
                  <year>2007</year>
                  <volume>67</volume>
                  <issue>3</issue>
                  <fpage>967</fpage>
                  <lpage>975</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3552</pub-id>
                  <?supplied-pmid 17283128?>
                  <pub-id pub-id-type="pmid">17283128</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Singh</surname>
                      <given-names>AP</given-names>
                    </name>
                    <name>
                      <surname>Bafna</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Chaudhary</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Venkatraman</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Eudy</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Johansson</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>MF</given-names>
                    </name>
                    <name>
                      <surname>Batra</surname>
                      <given-names>SK</given-names>
                    </name>
                  </person-group>
                  <article-title>Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells</article-title>
                  <source>Cancer Lett</source>
                  <year>2008</year>
                  <volume>259</volume>
                  <issue>1</issue>
                  <fpage>28</fpage>
                  <lpage>38</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.canlet.2007.09.018</pub-id>
                  <?supplied-pmid 17977648?>
                  <pub-id pub-id-type="pmid">17977648</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yap</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Olmos</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Brunetto</surname>
                      <given-names>AT</given-names>
                    </name>
                    <name>
                      <surname>Tunariu</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Barriuso</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Riisnaes</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Pope</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Clark</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Futreal</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Germuska</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Collins</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>deSouza</surname>
                      <given-names>NM</given-names>
                    </name>
                    <name>
                      <surname>Leach</surname>
                      <given-names>MO</given-names>
                    </name>
                    <name>
                      <surname>Savage</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Waghorne</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Chai</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Garmey</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Kaye</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>de Bono</surname>
                      <given-names>JS</given-names>
                    </name>
                  </person-group>
                  <article-title>Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies</article-title>
                  <source>J Clin Oncol</source>
                  <year>2011</year>
                  <volume>29</volume>
                  <issue>10</issue>
                  <fpage>1271</fpage>
                  <lpage>1279</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2010.31.0367</pub-id>
                  <?supplied-pmid 21383285?>
                  <pub-id pub-id-type="pmid">21383285</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Eathiraj</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Palma</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Volckova</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Hirschi</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>France</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Ashwell</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>TCK</given-names>
                    </name>
                  </person-group>
                  <article-title>Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-met) protein autophosphorylation by ARQ 197</article-title>
                  <source>J Biol Chem</source>
                  <year>2011</year>
                  <volume>286</volume>
                  <issue>23</issue>
                  <fpage>20666</fpage>
                  <lpage>20676</lpage>
                  <pub-id pub-id-type="doi">10.1074/jbc.M110.213801</pub-id>
                  <?supplied-pmid 21454604?>
                  <pub-id pub-id-type="pmid">21454604</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Munshi</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Jeay</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>CR</given-names>
                    </name>
                    <name>
                      <surname>France</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Ashwell</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Hill</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Moussa</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Leggett</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>CJ</given-names>
                    </name>
                  </person-group>
                  <article-title>ARQ 197, a novel and selective inhibitor of the human c-met receptor tyrosine kinase with antitumor activity</article-title>
                  <source>Mol Cancer Ther</source>
                  <year>2010</year>
                  <volume>9</volume>
                  <issue>6</issue>
                  <fpage>1544</fpage>
                  <lpage>1553</lpage>
                  <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-1173</pub-id>
                  <?supplied-pmid 20484018?>
                  <pub-id pub-id-type="pmid">20484018</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Basilico</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Pennacchietti</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Vigna</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Chiriaco</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Arena</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Bardelli</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Valdembri</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Serini</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Michieli</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2013</year>
                  <volume>19</volume>
                  <issue>9</issue>
                  <fpage>2381</fpage>
                  <lpage>2392</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-3459</pub-id>
                  <?supplied-pmid 23532890?>
                  <pub-id pub-id-type="pmid">23532890</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scher</surname>
                      <given-names>HI</given-names>
                    </name>
                    <name>
                      <surname>Halabi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Tannock</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Morris</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Sternberg</surname>
                      <given-names>CN</given-names>
                    </name>
                    <name>
                      <surname>Carducci</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Eisenberger</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Higano</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Bubley</surname>
                      <given-names>GJ</given-names>
                    </name>
                    <name>
                      <surname>Dreicer</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Petrylak</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Kantoff</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Basch</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Kelly</surname>
                      <given-names>WK</given-names>
                    </name>
                    <name>
                      <surname>Figg</surname>
                      <given-names>WD</given-names>
                    </name>
                    <name>
                      <surname>Small</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Beer</surname>
                      <given-names>TM</given-names>
                    </name>
                    <name>
                      <surname>Wilding</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Martin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Hussain</surname>
                      <given-names>M</given-names>
                    </name>
                    <collab>Prostate Cancer Clinical Trials Working Group</collab>
                  </person-group>
                  <article-title>Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate Cancer clinical trials working group</article-title>
                  <source>J Clin Oncol</source>
                  <year>2008</year>
                  <volume>26</volume>
                  <issue>7</issue>
                  <fpage>1148</fpage>
                  <lpage>1159</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2007.12.4487</pub-id>
                  <?supplied-pmid 18309951?>
                  <pub-id pub-id-type="pmid">18309951</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Friedman</surname>
                      <given-names>LF</given-names>
                    </name>
                    <name>
                      <surname>DeMets</surname>
                      <given-names>CD</given-names>
                    </name>
                  </person-group>
                  <source>DL, Fundamentals of Clinical trials</source>
                  <year>1998</year>
                  <publisher-loc>New York</publisher-loc>
                  <publisher-name>Springer-Verlag</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kang</surname>
                      <given-names>YK</given-names>
                    </name>
                    <name>
                      <surname>Muro</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Ryu</surname>
                      <given-names>MH</given-names>
                    </name>
                    <name>
                      <surname>Yasui</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Nishina</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Ryoo</surname>
                      <given-names>BY</given-names>
                    </name>
                    <name>
                      <surname>Kamiya</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Akinaga</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Boku</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>A phase II trial of a selective c-met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer</article-title>
                  <source>Investig New Drugs</source>
                  <year>2014</year>
                  <volume>32</volume>
                  <issue>2</issue>
                  <fpage>355</fpage>
                  <lpage>361</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10637-013-0057-2</pub-id>
                  <pub-id pub-id-type="pmid">24337769</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pant</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Patel</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kurkjian</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Hemphill</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Flores</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Thompson</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Bendell</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>A phase II study of the c-met inhibitor Tivantinib in combination with FOLFOX for the treatment of patients with previously untreated metastatic adenocarcinoma of the distal esophagus, Gastroesophageal junction, or stomach</article-title>
                  <source>Cancer Investig</source>
                  <year>2017</year>
                  <volume>35</volume>
                  <issue>7</issue>
                  <fpage>463</fpage>
                  <lpage>472</lpage>
                  <pub-id pub-id-type="doi">10.1080/07357907.2017.1337782</pub-id>
                  <pub-id pub-id-type="pmid">28662341</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Scagliotti</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>von Pawel</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Novello</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ramlau</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Favaretto</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Barlesi</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Akerley</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Orlov</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Santoro</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Spigel</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Hirsh</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Shepherd</surname>
                      <given-names>FA</given-names>
                    </name>
                    <name>
                      <surname>Sequist</surname>
                      <given-names>LV</given-names>
                    </name>
                    <name>
                      <surname>Sandler</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ross</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>von Roemeling</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Shuster</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Phase III multinational, randomized, double-blind, placebo-controlled study of Tivantinib (ARQ 197) plus Erlotinib versus Erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung Cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2015</year>
                  <volume>33</volume>
                  <issue>24</issue>
                  <fpage>2667</fpage>
                  <lpage>2674</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2014.60.7317</pub-id>
                  <?supplied-pmid 26169611?>
                  <pub-id pub-id-type="pmid">26169611</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tolaney</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Tan</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Guo</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Barry</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>van Allen</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Wagle</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Brock</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Larrabee</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Paweletz</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Ivanova</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Janne</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Overmoyer</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Wright</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Shapiro</surname>
                      <given-names>GI</given-names>
                    </name>
                    <name>
                      <surname>Winer</surname>
                      <given-names>EP</given-names>
                    </name>
                    <name>
                      <surname>Krop</surname>
                      <given-names>IE</given-names>
                    </name>
                  </person-group>
                  <article-title>Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer</article-title>
                  <source>Investig New Drugs</source>
                  <year>2015</year>
                  <volume>33</volume>
                  <issue>5</issue>
                  <fpage>1108</fpage>
                  <lpage>1114</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10637-015-0269-8</pub-id>
                  <pub-id pub-id-type="pmid">26123926</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <mixed-citation publication-type="other">Rimassa L et al (2017) Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): results of the METIV-HCC phase III trial. J Clin Oncol 35</mixed-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xiang</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Zhen</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Deng</surname>
                      <given-names>DYB</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma</article-title>
                  <source>J Exp Clin Cancer Res</source>
                  <year>2015</year>
                  <volume>34</volume>
                  <fpage>118</fpage>
                  <pub-id pub-id-type="doi">10.1186/s13046-015-0238-2</pub-id>
                  <?supplied-pmid 26458953?>
                  <pub-id pub-id-type="pmid">26458953</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Reuther</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Heinzle</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Spampatti</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Vlotides</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>de Toni</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Spöttl</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Maurer</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Nölting</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Göke</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Auernhammer</surname>
                      <given-names>CJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Cabozantinib and Tivantinib, but not INC280, induce Antiproliferative and Antimigratory effects in human neuroendocrine tumor cells in vitro: evidence for 'Off-Target' effects not mediated by c-met inhibition</article-title>
                  <source>Neuroendocrinology</source>
                  <year>2016</year>
                  <volume>103</volume>
                  <issue>3–4</issue>
                  <fpage>383</fpage>
                  <lpage>401</lpage>
                  <pub-id pub-id-type="doi">10.1159/000439431</pub-id>
                  <?supplied-pmid 26338447?>
                  <pub-id pub-id-type="pmid">26338447</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Michieli</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Di Nicolantonio</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?</article-title>
                  <source>Nat Rev Clin Oncol</source>
                  <year>2013</year>
                  <volume>10</volume>
                  <issue>7</issue>
                  <fpage>372</fpage>
                  <lpage>374</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrclinonc.2013.86</pub-id>
                  <?supplied-pmid 23712183?>
                  <pub-id pub-id-type="pmid">23712183</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ryan</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Rosenthal</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ng</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Alumkal</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Picus</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gravis</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Fizazi</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Forget</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Machiels</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Srinivas</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Zhu</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Tang</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Oliner</surname>
                      <given-names>KS</given-names>
                    </name>
                    <name>
                      <surname>Jiang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Loh</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Dubey</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Gerritsen</surname>
                      <given-names>WR</given-names>
                    </name>
                  </person-group>
                  <article-title>Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2013</year>
                  <volume>19</volume>
                  <issue>1</issue>
                  <fpage>215</fpage>
                  <lpage>224</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2605</pub-id>
                  <?supplied-pmid 23136195?>
                  <pub-id pub-id-type="pmid">23136195</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Michaelson</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Oudard</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ou</surname>
                      <given-names>YC</given-names>
                    </name>
                    <name>
                      <surname>Sengeløv</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Saad</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Houede</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Ostler</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Stenzl</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Daugaard</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Jones</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Laestadius</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Ullèn</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Bahl</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Castellano</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Gschwend</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Maurina</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Chow Maneval</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Lechuga</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Paolini</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2014</year>
                  <volume>32</volume>
                  <issue>2</issue>
                  <fpage>76</fpage>
                  <lpage>82</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2012.48.5268</pub-id>
                  <?supplied-pmid 24323035?>
                  <pub-id pub-id-type="pmid">24323035</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kelly</surname>
                      <given-names>WK</given-names>
                    </name>
                    <name>
                      <surname>Halabi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Carducci</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>George</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Mahoney</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Stadler</surname>
                      <given-names>WM</given-names>
                    </name>
                    <name>
                      <surname>Morris</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kantoff</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Monk</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Kaplan</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Vogelzang</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>Small</surname>
                      <given-names>EJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401</article-title>
                  <source>J Clin Oncol</source>
                  <year>2012</year>
                  <volume>30</volume>
                  <issue>13</issue>
                  <fpage>1534</fpage>
                  <lpage>1540</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2011.39.4767</pub-id>
                  <?supplied-pmid 22454414?>
                  <pub-id pub-id-type="pmid">22454414</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gignac</surname>
                      <given-names>GA</given-names>
                    </name>
                    <name>
                      <surname>Morris</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Heller</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>LH</given-names>
                    </name>
                    <name>
                      <surname>Scher</surname>
                      <given-names>HI</given-names>
                    </name>
                  </person-group>
                  <article-title>Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of babel</article-title>
                  <source>Cancer</source>
                  <year>2008</year>
                  <volume>113</volume>
                  <issue>5</issue>
                  <fpage>966</fpage>
                  <lpage>974</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.23719</pub-id>
                  <?supplied-pmid 18661513?>
                  <pub-id pub-id-type="pmid">18661513</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smith</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>de Bono</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sternberg</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>le Moulec</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Oudard</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>de Giorgi</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Krainer</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Bergman</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Hoelzer</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>de Wit</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Bögemann</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Saad</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Cruciani</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Thiery-Vuillemin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Feyerabend</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Miller</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Houédé</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Hussain</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Lam</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Polikoff</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Stenzl</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Mainwaring</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Ramies</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Hessel</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Weitzman</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Fizazi</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Phase III study of Cabozantinib in previously treated metastatic castration-resistant prostate Cancer: COMET-1</article-title>
                  <source>J Clin Oncol</source>
                  <year>2016</year>
                  <volume>34</volume>
                  <issue>25</issue>
                  <fpage>3005</fpage>
                  <lpage>3013</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2015.65.5597</pub-id>
                  <?supplied-pmid 27400947?>
                  <pub-id pub-id-type="pmid">27400947</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smith</surname>
                      <given-names>DC</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Sweeney</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Elfiky</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Logothetis</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Corn</surname>
                      <given-names>PG</given-names>
                    </name>
                    <name>
                      <surname>Vogelzang</surname>
                      <given-names>NJ</given-names>
                    </name>
                    <name>
                      <surname>Small</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Harzstark</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Gordon</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Vaishampayan</surname>
                      <given-names>UN</given-names>
                    </name>
                    <name>
                      <surname>Haas</surname>
                      <given-names>NB</given-names>
                    </name>
                    <name>
                      <surname>Spira</surname>
                      <given-names>AI</given-names>
                    </name>
                    <name>
                      <surname>Lara</surname>
                      <given-names>PN</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>CC</given-names>
                    </name>
                    <name>
                      <surname>Srinivas</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Sella</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Schöffski</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Scheffold</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Weitzman</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Hussain</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial</article-title>
                  <source>J Clin Oncol</source>
                  <year>2013</year>
                  <volume>31</volume>
                  <issue>4</issue>
                  <fpage>412</fpage>
                  <lpage>419</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2012.45.0494</pub-id>
                  <?supplied-pmid 23169517?>
                  <pub-id pub-id-type="pmid">23169517</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fleming</surname>
                      <given-names>TR</given-names>
                    </name>
                    <name>
                      <surname>Rothmann</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Lu</surname>
                      <given-names>HL</given-names>
                    </name>
                  </person-group>
                  <article-title>Issues in using progression-free survival when evaluating oncology products</article-title>
                  <source>J Clin Oncol</source>
                  <year>2009</year>
                  <volume>27</volume>
                  <issue>17</issue>
                  <fpage>2874</fpage>
                  <lpage>2880</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2008.20.4107</pub-id>
                  <?supplied-pmid 19414672?>
                  <pub-id pub-id-type="pmid">19414672</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
